CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

1 . A compound of Formula 6

characterized in that

said compound has a sodium content from 7.2% w/w to 7.7% w/w;

and/or

a test solution of 2.5% w/v of said compound in water is equally or less colored than any one of reference solutions Y 5 , BY 5 , GY 5 , or B 5 ; as determined according to Chapter 2.2.2. of the European Pharmacopoeia 6.0; and/or

said compound is crystalline;

and/or

said compound is in a non-hydrated form;

and/or

said compound is in a non-solvated form;

and/or

said compound has an assay of at least 98% w/w, as determined by high-performance liquid chromatography; and/or

said compound comprises a total amount of impurities of not more than 2% w/w, as determined by high-performance liquid chromatography;

and/or

said compound comprises a total amount of residual solvents of less than 1% w/w, wherein the solvents are selected from a group consisting of ethanol, methanol, tetrahydrofuran, dimethylformamide, and ethylene glycol; as determined by gas chromatography.

2 . A compound according to claim 1 , wherein said compound is crystalline, wherein said crystalline compound is characterized by an X-ray powder diffractogram with at least four peaks having an angle of refraction 2θ selected from: 9.4°, 12.0°, 13.2°, 17.7°, 18.4°, 19.8°, 21.2°, 21.9°, and 24.9°.

3 . A compound according to claim 1 , wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, and 21.9°.

4 . A compound according to claim 1 , wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, 18.4°, 21.2°, and 21.9°.

5 . A compound according to claim 1 , wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, 13.2°, 17.7°, 18.4°, 19.8°, 21.2°, 21.9°, and 24.9°.

6 . A compound according to claim 1 , wherein said compound is crystalline, wherein said crystalline compound is characterized in that the X-ray powder diffractogram essentially shows the pattern as depicted in FIG. 1 .

7 . A process for the preparation of the compound of Formula 6 according to claim 1 , said process comprising the following steps

(e) reacting the compound of Formula 5 or a solvate thereof

with a sodium containing base, to give the compound of Formula 6

(f) purifying the compound of Formula 6 by

(f1) recrystallizing the compound of Formula 6 in water at pH≥7;

and

(f2) triturating the compound of Formula 6 in a solvent selected from methanol, ethanol, or a mixture thereof;

(g) drying the compound of Formula 6.

8 . A process according to claim 7 , said process comprising the following steps

(a) reacting the compound of Formula 1

with 5-methyl-pyridine-2-sulfonamide or a salt thereof, under basic conditions, to give the compound of Formula 2 or a salt thereof

(b) reacting the compound of Formula 2 or a salt thereof with ethylene glycol in the presence of an alkali metal hydroxide, to give the compound of Formula 3 or a salt thereof

(c) reacting the compound of Formula 3 or a salt thereof with trimethylsilyl cyanide in the presence of a mono-, di-, or tri-C 1-4 -alkyl amine, to give the compound of Formula 4

(d) reacting the compound of Formula 4 with an alkali metal azide in the presence of ammonium chloride, to give the compound of Formula 5 or a solvate thereof

and (e), (f), and (g), each according to claim 7 .

9 . A pharmaceutical composition comprising the compound according to claim 1 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

10 . A pharmaceutical composition according to claim 9 , said composition comprising

from 23.5 mg/ml to 26.5 mg/ml of the compound, wherein said concentration refers to the compound in its free acid form;

from 8.0 mg/mL to 12.0 mg/mL tris(hydroxymethyl)aminomethane;

from 0.08 mg/ml to 0.12 mg/mL disodium edetate;

from 2.0 mg/mL to 3.0 mg/mL sodium chloride; and

water;

wherein the pH value of said composition is from 7.0 to 9.0.

11 . A pharmaceutical composition according to claim 10 , wherein said composition is equally or less colored than reference solution GY 3 , as determined according to Chapter 2.2.2. of the European Pharmacopoeia 6.0.

12 . (canceled)

13 . A method for the prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery/securing, wherein said method comprises administering to a subject in need thereof an effective amount of the compound according to claim 1 .

14 . A method for the prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery, wherein said method comprises dissolving the compound according to claim 1 in an aqueous solution to form a pharmaceutical composition suitable for intravenous administration and administering to a subject in need thereof a said pharmaceutical composition as an intravenous continuous infusion at a dosage of 10 mg/h, wherein said dosage refers to the amount of the compound in its free acid form, wherein said administration starts after surgery of aneurysmal subarachnoid hemorrhage and continues for up to 15 days after aneurysmal rupture.

15 . (canceled)

16 . A pharmaceutical composition comprising the compound according to claim 2 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

17 . A pharmaceutical composition comprising the compound according to claim 3 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

18 . A pharmaceutical composition comprising the compound according to claim 4 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

19 . A pharmaceutical composition comprising the compound according to claim 5 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

20 . A pharmaceutical composition comprising the compound according to claim 6 , wherein said composition further comprises at least one pharmaceutically acceptable carrier.

21 . A process for the preparation of a pharmaceutical composition comprising Formula 6

wherein said process comprises mixing the compound according to claim 1 with at least one pharmaceutically acceptable carrier.